In patients with severe hereditary factor V deficiency (residual activity < 5%) plasma shall be transfused with a dose of 15–20ml/kg body weight perioperatively, in the context of invasive procedures or in cases of severe bleeding with the objective of maintaining hemostatically effective plasma levels of 15–20%. |
1 C+ |
Plasma exchange with 40ml/kg body weight could be performed perioperatively or in the context of invasive procedures in patients with severe hereditary factor V deficiency (residual activity < 5%), in whom a hemostatically effective factor V level in plasma cannot be achieved by plasma transfusion. |
2 C |
In patients with severe hereditary factor XI deficiency (residual activity < 5%) plasma shall be transfused with a dose of 20 ml/kg body weight perioperatively, in the context of invasive procedures or in cases of severe bleeding with the objective of maintaining hemostatically effective plasma levels of 20% when local measures (e.g. fibrin sealant), desmopressin (DDVAP) and antifibrinolytic drugs are insufficient to achieve hemostasis. |
1 C+ |
Plasma exchange with 40ml/kg body weight could be performed perioperatively, in the context of invasive procedures or in cases of severe bleeding in patients with severe hereditary factor XI deficiency (residual activity <5%), in whom a hemostatically effective plasma factor XI level cannot be achieved by plasma transfusion. |
2 C |
In patients with mild hereditary factor XI deficiency and a disposition to severe bleeding plasma shall be transfused with a dose of 20ml/kg body weight perioperatively or in the context of invasive procedures when local measures (e.g. fibrin sealant), desmopressin (DDVAP) and antifibrinolytic drugs are insufficient to achieve hemostasis. |
1 C+ |